CD36 as a target for metabolic modulation therapy in cardiac disease

References

• Wende AR, Brahma MK, McGinnis GR, et al. Metabolic origins of heart failure. JACC Basic Transl Science. 2017;2:297–310.
   PubMedGoogle Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocrinol Metabol Disorders. 2010;11(1):31–39.
   PubMed Web of Science ®Google Scholar
• Noordali H, Loudon BL, Frenneaux MP, et al. Cardiac metabolism – a promising therapeutic target for heart failure. Pharmacol Therap. 2018;182:95–114.
   PubMed Web of Science ®Google Scholar
• Zuurbier CJ, Bertrand L, Beualoye CR, et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J Cell Mol Med. 2020;24(11):5937–5954.
   PubMed Web of Science ®Google Scholar
• Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–1129.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Luiken JJFP. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. J Lipid Res. 2018;59(7):1084–1093.
   PubMed Web of Science ®Google Scholar
• Shu H, Peng Y, Hang W, et al. The role of CD36 in cardiovascular disease. Cardiovasc Res. 2021; in press. DOI:10.1093/cvr/cvaa319.
   Google Scholar
• Clemetson KJ, Pfueller ST, Luscher EF, et al. Isolation of the membrane glycoproteins of human platelets by lectin affinity chromatography. Biochim Biophys Acta. 1977;464(3):493–508.
   PubMedGoogle Scholar
• Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268(16):11811–11816.
   PubMed Web of Science ®Google Scholar
• Abumrad NA, El-Maghrabi MR, Amri EZ, et al. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 1993;268(24):17665–17668.
   PubMed Web of Science ®Google Scholar
• Van Nieuwenhoven FA, Verstijnen CP, Abumrad NA, et al. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem Biophys Res Commun. 1995;207(2):747–752.
   PubMed Web of Science ®Google Scholar
• Son N-H, Basu D, Samovski D, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake. J Clin Invest. 2018;128(10):4329–4342.
   PubMed Web of Science ®Google Scholar
• Luiken JJFP, Chanda D, Nabben M, et al. Post-translational modifications of CD36 (SR-B2): implications for regulation of myocellular fatty acids uptake. Biochim Biophys Acta. 2016;1862(12):2253–2258.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Luiken JJFP. Time for a détente in the war on the mechanism of cellular fatty acid uptake. J Lipid Res. 2020;61(9):1300–1303.
   PubMed Web of Science ®Google Scholar
• Bonen A, Luiken JJFP, Arumugam Y, et al. Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid translocase. J Biol Chem. 2000;275(19):14501–14508.
   PubMed Web of Science ®Google Scholar
• Smith BK, Jain SS, Rimbaud S, et al. FAT/CD36 is located on the outer mitochondrial membrane, upstream of long-chain acyl-CoA synthetase, and regulates palmitate oxidation. Biochem J. 2011;437(1):125–134.
   PubMedGoogle Scholar
• Klip A, McGraw TE, James DE. Thirty sweet years of GLUT4. J Biol Chem. 2019;294:11369–11381.
   PubMed Web of Science ®Google Scholar
• Neels JG, Grimaldi PA. Physiological functions of peroxisome proliferator-activated receptor β. Physiol Rev. 2014;94(3):795–858.
   PubMed Web of Science ®Google Scholar
• Samovski D, Dhule P, Pietka T, et al. Regulation of insulin receptor pathway and glucose metabolism by CD36 signaling. Diabetes. 2018;67(7):1272–1284.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Luiken JJFP. From fat to FAT (CD36/SR-B2): understanding the regulation of cellular fatty acid uptake. Biochimie. 2017;136:21–26.
   PubMed Web of Science ®Google Scholar
• Liu Y, Steinbusch LKM, Nabben M, et al. Palmitate-induced vacuolar-Type H+-ATPase inhibition feeds forward into insulin resistance and contractile dysfunction. Diabetes. 2017;66(6):1521–1534.
   PubMed Web of Science ®Google Scholar
• Zhu B, Li MY, Lin Q, et al. Lipid oversupply induces CD36 sarcolemmal translocation via dual modulation of PKCζ and TBC1D1: an early event prior to insulin resistance. Theranostics. 2020;10(3):1332–1354.
   PubMed Web of Science ®Google Scholar
• Angin Y, Steinbusch LKM, Simons PJ, et al. CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem J. 2012;448(1):43–53.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Nabben M, Young ME, et al. Re-balancing cellular energy substrate metabolism to mend the failing heart. Biochim Biophys Acta. 2020;1866(5):165579.
   Web of Science ®Google Scholar
• Sung MM, Byrne NJ, Kim TT, et al. Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure. Am J Physiol. 2017;312:H552–H560.
   Google Scholar
• Tanaka T, Nakata T, Oka T, et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res. 2001;2001(42):751–759.
   Google Scholar
• Miyazaki M, Suematsu Y, Kato S, et al. Type 1 cluster of differentiation 36 deficiency-related cardiomyopathy accelerates heart failure with co-existing mitral valve prolapse: a case report. Eur Heart J Case Rep. 2019;3:1–5.
   Google Scholar
• Heather LC, Pates KM, Atherton HJ, et al. Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. Circ Heart Fail. 2013;6(5):1058–1066.
   PubMed Web of Science ®Google Scholar
• Nedvedova I, Kolar D, Neckar J, et al. Cardioprotective regimen of adaptation to chronic hypoxia diversely alters myocardial gene expression in SHR and SHR-mtBN conplastic rat strains. Front Endocrinol. 2019;9:809.
   PubMed Web of Science ®Google Scholar
• Irie H, Krukenkamp IB, Brinkmann JFF, et al. Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc Natl Acad Sci USA. 2003;100(11):6819–6824.
   PubMed Web of Science ®Google Scholar
• Neckár J, Silhavy J, Zídek V, et al. CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis. Physiol Genomics. 2012;44(2):173–182.
   PubMed Web of Science ®Google Scholar
• Yang J, Sambandam N, Han X, et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res. 2007;100(8):1208–1217.
   PubMed Web of Science ®Google Scholar
• Dirkx E, Van Eys GJJM, Schwenk RW, et al. Protein kinase-D1 overexpression prevents lipid-induced cardiac insulin resistance. J Mol Cell Cardiol. 2014;76:208–217.
   PubMed Web of Science ®Google Scholar
• Bessi VL, Labbé SM, Huynh DN, et al. EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice. Cardiovasc Res. 2012;96(1):99–108.
   PubMed Web of Science ®Google Scholar
• Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med. 2009;13(5):811–825.
   PubMed Web of Science ®Google Scholar
• Coort SLM, Willems J, Coumans WA, et al. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem. 2002;239(1/2):213–219.
   PubMed Web of Science ®Google Scholar
• Kuda O, Pietka TA, Demianova Z, et al. Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 Lysine 164. J Biol Chem. 2013;288(22):15547–15555.
   PubMed Web of Science ®Google Scholar
• Mansor LS, da Luz Sousa Fialho M, Yea G, et al. Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Cardiovasc Res. 2017;113(7):737–748.
   PubMed Web of Science ®Google Scholar
• Khan S, Kowluru A. CD36 mediates lipid accumulation in pancreatic beta cells under the duress of glucolipotoxic conditions: novel roles of lysine deacetylases. Biochem Biophys Res Commun. 2018;495(3):2221–2226.
   PubMed Web of Science ®Google Scholar
• Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. Review J Geriatr Cardiol. 2014;11(3):253–258.
   PubMed Web of Science ®Google Scholar
• Huang J, Li Y, Zhang J, et al. The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway. Int Heart J. 2017;58(2):257–263.
   PubMed Web of Science ®Google Scholar
• Zheng A, Cao L, Qin S, et al. Exenatide regulates substrate preferences through the p38 γ MAPK pathway after ischaemia/reperfusion injury in a rat heart. Heart Lung Circ. 2017;26(4):404–412.
   PubMed Web of Science ®Google Scholar
• Geloen A, Helin L, Geeraert B, et al. CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS ONE. 2012;7(5):e37633.
   PubMed Web of Science ®Google Scholar
• Bai L, Li X, He L, et al. Antidiabetic potential of flavonoids from traditional Chinese medicine: a review. Am J Chin Med. 2019;47(5):933–957.
   PubMed Web of Science ®Google Scholar
• Qin H, Zhang Y, Wang R, et al. Puerarin suppresses Na+-K+-APTase-mediated systemic inflammation and CD36 expression, and alleviates cardiac lipotoxicity in vitro and in vivo. J Cardiovasc Pharmacol. 2016;68(6):465–472.
   PubMed Web of Science ®Google Scholar
• Chen X-F, Wang L, Wu Y-Z, et al. Effect of puerarin in promoting fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle in diabetic rats. Nutr Diab. 2018;8(1):1.
   Google Scholar
• Chen Y, Li Y, Wang Y, et al. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor γ and fatty acid transferase expression. Metab Clin Exper. 2009;58(12):1694–1702.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang S, Zhang X, et al. Artemisinin reduces lipid accumulation in hepatocytes by inhibition of CD36 expression. Indian J Pharmaceut Educ Res. 2017;51(3):393–400.
   Web of Science ®Google Scholar
• Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.
   PubMed Web of Science ®Google Scholar
• Febbraio M, Hajjar CP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785–791.
   PubMed Web of Science ®Google Scholar
• Lindsey ML, Jung M, Yabluchanskiy A, et al. Exogenous CXCL4 infusion inhibits macrophage phagocytosis by limiting CD36 signalling to enhance post-myocardial infarction cardiac dilation and mortality. Cardiovasc Res. 2019;115(2):395–408.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Luiken JJFP, Nabben M. CD36 (SR-B2) as a target to treat lipid overload-induced cardiac dysfunction. J Lipid Atheroscl. 2020;9(1):66–78.
   PubMedGoogle Scholar
• Chi RJ, Harrison MS, Burd CG. Biogenesis of endosome-derived transport carriers. Cell Mol Life Sci. 2015;72(18):3441–3455.
   PubMed Web of Science ®Google Scholar
• Larance M, Ramm G, Stöckli J, et al. Characterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking. J Biol Chem. 2005;280(45):37803–37813.
   PubMed Web of Science ®Google Scholar
• Schwenk RW, Dirkx E, Coumans WA, et al. Requirement for distinct vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia. 2010;53(10):2209–2219.
   PubMed Web of Science ®Google Scholar
• Jucker BM, Doe CP, Schnackenberg CG, et al. PPAR δ activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol. 2007;50(1):25–34.
   PubMed Web of Science ®Google Scholar
• Hsieh FL, Turner L, Bolla JR, et al. The structural basis for CD36 binding by the malaria parasite. Nat Commun. 2016;7(1):12837.
   PubMedGoogle Scholar
• Wang L, Bao Y, Yang Y, et al. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay. J Biomol Screening. 2010;15(3):239–250.
   PubMedGoogle Scholar